Fundraising Fox
Thetis Pharmaceuticals LLC
Southport, US · Founded 2011 · Connecticut LLC · 3 known investors
Find your way into Thetis Pharmaceuticals LLC
Sign up to see every warm intro you have to Thetis Pharmaceuticals LLC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Thetis Pharmaceuticals LLC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.
Founders & leadership
Thetis Pharmaceuticals LLC was founded in 2011 by Frank C Sciavolino and Gary Mathias.
FC
Frank C SciavolinoCo-Founder, President & Chief Scientific OfficerDr. Sciavolino spent 35 years at Pfizer Global R&D in various management and scientific roles across drug discovery, development, and registration, including work on antibiotic and COX-2 inhibitor programs, and served as Vice President overseeing R&D operations across multiple sites. He holds a Ph.D. in organic chemistry from the University of Michigan and a B.S. in pharmacy from St. John's University.
JP
John ParkinsonChief Science Officer
JS
Joyce SteinbergChief Medical Officer
WO
Walter OgierManager
FC
Fabio CataldiManager
DC
David CookManager
Board
DM
David M WurzerManager
AM
Alan MendelsonManager
DW
Dennis WillsonManager
Investors · 3
Also in the syndicate · 1
Helmsley Charitable Trust
Reported raises · per SEC filings
Form D private placements$8M disclosed across 5 of 6 rounds · 2016–2026
▶$560.3KraisedOct 2026 · 10 investors · PharmaceuticalsRule 506(b)
▶$560.3KraisedOct 2026 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary MathiasExecutive Officer, Director
- Walter OgierDirector
- Frank C. SciavolinoDirector
- Dennis WillsonDirector
- Fabio CataldiDirector
- David CookDirector
- Offering amount
- $1M
- Amount sold
- $560.3K
- First sale
- Aug 2026
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.1MraisedJul 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJul 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary MathiasExecutive Officer, Director
- Frank C. SciavolinoDirector
- Walter OgierDirector
- Cynthia GreenDirector
- Dennis F. WillsonDirector
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$795.8KraisedAug 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$795.8KraisedAug 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M WurzerDirector
- Frank C SciavolinoExecutive Officer, Director
- Dennis F WillsonDirector
- Gary MathiasExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $2.1M
- Amount sold
- $795.8K
- First sale
- Aug 2018
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$4.1MraisedJan 2017 · 52 investors · PharmaceuticalsRule 506(b)
▶$4.1MraisedJan 2017 · 52 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis F WillsonDirector
- David M WurzerDirector
- Gary F MathiasExecutive Officer, Director
- Frank C SciavolinoExecutive Officer, Director
- Walter OgierDirector
- Offering amount
- $8M
- Amount sold
- $4.1M
- Sales commissions
- $200K
- Placement agents
- Fairport Capital, Inc.
- First sale
- Jun 2016
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.4MraisedFeb 2016 · 16 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedFeb 2016 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary F MathiasExecutive Officer, Director
- Dennis WillsonDirector
- David M WurzerDirector
- Frank C SciavolinoDirector
- Alan MendelsonDirector
- Offering amount
- $4M
- Amount sold
- $1.4M
- First sale
- Jan 2016
- Incorporated
- Limited Liability Company, Connecticut, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
NovartisNovartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions. Its medicines include treatments for HR+/HER2- early breast cancer and polymyalgia rheumatica.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Companies working in the same space as Thetis Pharmaceuticals LLC.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $997.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $398.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $295.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $293.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $205.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $206K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Thetis Pharmaceuticals LLC do?
- Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance. It is being developed for inflammatory bowel disease, including ulcerative colitis, and solid tumors.
- Who founded Thetis Pharmaceuticals LLC?
- Thetis Pharmaceuticals LLC was founded by Frank C Sciavolino, Gary Mathias in 2011.
- Who are Thetis Pharmaceuticals LLC's investors?
- Thetis Pharmaceuticals LLC's investors include Connecticut Innovations, Freemind Investments.
- How much funding has Thetis Pharmaceuticals LLC raised?
- Thetis Pharmaceuticals LLC has disclosed $8M raised across 5 of its 6 known rounds.
- Where is Thetis Pharmaceuticals LLC headquartered?
- Thetis Pharmaceuticals LLC is headquartered in Southport, US.